Revenio Group Corporation: Revenio to begin the buy-back of its own shares

Report this content

Revenio Group Corporation, Stock Exchange Release, November 6, 2018 at 10:15

Revenio Group Corporation: Revenio to begin the buy-back of its own shares

The Board of Directors of Revenio Group Corporation has decided to use the authorization given by the Annual General Meeting of 20 March 2018 to buy back the company's own shares by initiating a share buy-back program.

The share buy-back will begin at the earliest on November 6, 2018 and end at the latest on December 20, 2018. The maximum number of shares to be bought back is 50,000, which represents 0.21 per cent of all shares in Revenio Group Corporation. The maximum sum to be used for share acquisitions under the buy-back program is EUR 825,000.

The shares will be acquired to fulfil obligations related to the Company's share-based commitment and incentive schemes.

The shares will be acquired with the Company's non-restricted equity, otherwise than in proportion to the shareholders' shareholdings. The shares will be acquired at the market price quoted in public trading organized by Nasdaq Helsinki Ltd on a regulated market at the time of acquisition. The number of shares to be acquired cannot exceed 25 per cent of the average daily trading volume of Revenio Group Corporation's shares. The average daily volume is based on the average daily volume of the 20 trading days preceding each trading day.

On 20 March 2018, the AGM authorized the Board to make the decision to buy back a maximum of 2,393,821 of the company's own shares in one or several tranches using the Company's non-restricted equity.

Revenio Group Corporation has a total of 23,947,905 shares and currently owns 6,213 treasury shares.

Revenio Group Corporation

Board of Directors

For further information, please contact:
Timo Hildén, CEO, tel.  +358 40 580 4774


Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media 

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2017, net sales of Revenio Group totaled MEUR 26.8, with an operating margin of 35.5%, excluding non-recurring expenses. Revenio Group Corporation is listed on Nasdaq Helsinki.